NRIX - Nurix Therapeutics

-

$undefined

N/A

(N/A)

Nurix Therapeutics NASDAQ:NRIX Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.

Location: | Website: www.nurixtx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

990.9M

Cash

448.1M

Avg Qtr Burn

-24.29M

Short % of Float

18.78%

Insider Ownership

1.45%

Institutional Own.

97.75%

Qtr Updated

08/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NX-5948 Details
Cancer, B-cell malignancies

Phase 1

Data readout

NX-5948 Details
Waldenstrom macroglobulinemia

Phase 1

Data readout

NX-2127 Details
Non-Hodgkin lymphoma, Blood cancer, Cancer, B-cell malignancies, Chronic lymphocytic leukemia, Mantle cell lymphoma, Diffuse large B cell lymphoma

Phase 1

Data readout

NX-1607 Details
Solid tumor/s, Cancer

Phase 1

Data readout

NX-1607 + paclitaxel Details
Solid tumor/s, Cancer

Phase 1a

Data readout

DeTIL-0255 Details
Ovarian cancer, Cancer, Cervical cancer, Endometrial cancer

Failed

Discontinued